MSI-1436 is primarily researched for its potential therapeutic applications, particularly in the treatment of obesity and type 2 diabetes. It functions as an inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme that plays a key role in regulating metabolic pathways. By inhibiting PTP1B, MSI-1436 enhances insulin sensitivity and leptin signaling, which can lead to improved glucose metabolism and reduced appetite. This makes it a promising candidate for managing metabolic disorders. Additionally, studies have explored its potential in treating certain cancers, as PTP1B is also involved in cell growth and survival pathways. Its ability to modulate these pathways suggests it could be useful in oncology, though research in this area is still in early stages.